Eye on the Cure Podcast | Episode 73: Dr. Zuhal Butuner
Eye on the Cure
Dr. Zuhal Butuner talks about her company’s two emerging RNA therapies for LCA10 and USH2A.
September 20, 2024. Dr. Zuhal Butuner, chief medical officer at Sepul Bio, talks with host Ben Shaberman about her company's two emerging RNA therapies – sepofarsen (for LCA10) and ultevursen (for USH2A) – formerly in clinical trials sponsored by ProQR. Dr. Butuner discusses how the RNA treatments work, what was learned from earlier clinical trials, and Sepul Bio's plans to move the therapies back into human studies.
